Upright proton therapy for cancer patients
This trial tests a new way to deliver proton therapy while you're sitting upright instead of lying down. It aims to see if this position is more comfortable and effective for cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have any type of cancer
- Your doctor recommends proton therapy as part of your treatment
- You can be a child or an adult
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a precise type of radiation called proton therapy can work well for cervical cancer that has spread to lymph nodes. It aims to see if this treatment can shrink tumors with fewer side effects.
This study tests a new software system used to plan and manage proton therapy, a type of radiation treatment that targets tumors precisely. It aims to see if the software works well in routine care, which could improve treatment for future patients.
This trial tests a new type of proton radiation for early-stage non-small cell lung cancer. It aims to see if it's safe and works well, with less damage to healthy tissue.
This trial tests a precise form of proton radiation for people with early stage lung cancer who cannot have surgery. It aims to see if this treatment is effective and safe.
This trial studies whether proton beam radiation after surgery can better treat certain uterine (endometrial) or cervix (cervical) cancers. It may help by targeting the pelvic area while limiting radiation to nearby organs.
This trial compares two types of radiation (standard photon vs. newer proton) for people with newly diagnosed endometrial or cervical cancer. It aims to see if proton therapy reduces side effects while controlling the cancer just as well.
Hear when a new Proton Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.